Skip to main content
C

CELLUMED CO., LTD. — Investor Relations & Filings

Ticker · 049180 ISIN · KR7049180003 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2022-12-16 Legal Proceedings Report
Country KR South Korea
Listing KO 049180

About CELLUMED CO., LTD.

http://www.clnzyme.co.kr/

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices, tissue grafts, and advanced biologics. The company operates as a human tissue bank, producing and supplying a variety of bone graft materials, including allografts and xenografts, for transplantation. Its medical device portfolio features orthopedic implants, with a key product being an artificial knee joint system. In the biologics sector, Cellumed develops growth factors and provides specialized enzymes, such as CLnZyme, which are utilized in the research, development, and production of RNA-based vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
소송등의제기ㆍ신청(일정금액이상의청구)
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory filing from the Korean Exchange (KRX) system regarding a 'Lawsuit/Legal Proceeding' (소송등의제기ㆍ신청). It details a specific legal claim (enforcement of a foreign judgment) against the company, including the plaintiff, the claim amount, the court, and the company's planned response. This fits the definition of a Legal Proceedings Report (LTR) as it concerns significant litigation and regulatory/legal matters.
2022-12-16 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (the 38th Annual General Meeting). It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the announcement as a regulatory disclosure regarding meeting logistics, it fits best under the RNS category as a general regulatory filing.
2022-12-14 Korean
전환청구권행사(제24회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal notification regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (제24회차) by the company Cellumed. It details the number of shares issued, the conversion price, and the remaining balance of the convertible bonds. This type of filing relates to changes in capital structure resulting from the conversion of debt into equity, which falls under the category of share issues or capital changes.
2022-12-06 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제24회차)
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from Cellumed regarding the acquisition of convertible bonds before maturity (Put Option exercise). It details the bond series, acquisition amount, acquisition date, and the method of cancellation. This falls under capital structure changes and financing updates, specifically related to debt instruments. Given the specific nature of bond buybacks/repayments, it fits best under the 'Capital/Financing Update' category.
2022-12-02 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Cellumed' (주식회사 셀루메드) covering the period from January 1, 2022, to September 30, 2022. It contains detailed business descriptions, market analysis, and product information, which are characteristic of a comprehensive interim financial report. It is not an announcement of a report, but the report itself, and it contains substantive business and operational data. 9M 2022
2022-11-14 Korean
전환가액의조정(제24,25회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from the Korean Exchange (KRX) system regarding the adjustment of conversion prices for convertible bonds (Series 24 and 25) issued by Cellumed. It details the change in conversion price due to market price fluctuations, the impact on the number of convertible shares, and the legal basis for the adjustment. This falls under capital structure changes related to debt-to-equity instruments, which is best classified as a Capital/Financing Update (CAP).
2022-10-04 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.